Impaired glucose homeostasis in renal transplant recipients receiving basiliximab
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The pathogenesis of new onset diabetes after transplantation (NODAT) is multifactorial. Suppression of regulatory T lymphocytes may have a negative impact on pancreatic beta-cells. Induction with basiliximab affects regulatory T-cell function and may therefore, theoretically, also affect glucose homeostasis in renal transplant recipients. METHODS: All kidney recipients > or =50 years of age without diabetes mellitus transplanted from 1 January 2005 to 31 December 2007 were included in a single-centre retrospective study. Immunosuppression consisted of steroids, mycophenolate mofetil and cyclosporine. Basiliximab was introduced as induction therapy 1 January 2007. An oral glucose tolerance test (OGTT) was performed in all patients 10 weeks post-transplant. RESULTS: A total of 264 patients were recruited. One hundred and thirty-four patients received basiliximab. In the basiliximab group, 51.5% developed NODAT, impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) versus 36.9% in the group without induction therapy (P = 0.017). In recipients with normal OGTT, the mean fasting glucose at 10 weeks was 5.18 mmol/l (SD: 0.54) in the basiliximab group (n = 65) and 4.84 mmol/l (SD: 0.64) in the no induction group (n = 82) (P = 0.001). CONCLUSION: Use of basiliximab as induction therapy may be associated with impaired glucose homeostasis after kidney transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Testosterone may impair gonadotropin secretion and result in impaired spermatogenesis.1570”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1570]
Citations
Cites
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Diabetes Mellitus after Kidney Transplantation in the United States
Kasiske, B. L., Snyder, J. J., Gilbertson, D., & Matas, A. J. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00010.x · Cited by 1,285
Setoguchi, R., Hori, S., Takahashi, T., & Sakaguchi, S. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041982 · Cited by 1,235
Heisel, O., Heisel, R., Balshaw, R., & Keown, P. (2004) · American Journal of Transplantation · doi:10.1046/j.1600-6143.2003.00372.x · Cited by 506 · cited 8×
“Younger recipients were excluded because the immunosuppressive regimen for this age group changed CNI from cyclosporine (CsA) to tacrolimus (Tac) in January 2007.”
BackgroundResultInfluentialCosio, F. G., Pesavento, T. E., Osei, K., Henry, M. L., & Ferguson, R. M. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.059002732.x · Cited by 381
Sirolimus Is Associated with New-Onset Diabetes in Kidney Transplant Recipients
Johnston, O., Rose, C. L., Webster, A. C., & Gill, J. S. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007111202 · Cited by 359
Hjelmesæth, J., Hartmann, A., Leivestad, T., Holdaas, H., Sagedal, S., Olstad, M., & Jenssen, T. (2006) · Kidney International · doi:10.1038/sj.ki.5000116 · Cited by 345
Self-citationGLUCOSE INTOLERANCE AFTER RENAL TRANSPLANTATION DEPENDS UPON PREDNISOLONE DOSE AND RECIPIENT AGE1
Hjelmes??th, J., Hartmann, A., Kofstad, J., Stenstr??m, J., Leivestad, T., Egeland, T., & Fauchald, P. (1997) · Transplantation · doi:10.1097/00007890-199710150-00008 · Cited by 309
Self-citationBluestone, J. A., Liu, W., Yabu, J. M., Laszik, Z. G., Putnam, A., Belingheri, M., Gross, D. M., Townsend, R. M., & Vincenti, F. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02377.x · Cited by 233
Hjelmes�th, J., Sagedal, S., Hartmann, A., Rollag, H., Egeland, T., Hagen, M., Nordal, K. P., & Jenssen, T. (2004) · Diabetologia · doi:10.1007/s00125-004-1499-z · Cited by 228
Self-citation
Research works printed but not linked: 1
- 2008, Transplant international : official journal of the European Society for Organ Transplantation, 6, 523
Cited by
Sharif, A., Hecking, M., de Vries, A. P. J., Porrini, E., Hornum, M., Rasoul-Rockenschaub, S., Berlakovich, G., Krebs, M., Kautzky-Willer, A., Schernthaner, G., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12850 · Cited by 532
“017) at 10 weeks posttransplantation (45).”
Self-citationBlonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
New-Onset Diabetes After Kidney Transplantation—Changes and Challenges
Yates, C. J., Fourlanos, S., Hjelmesæth, J., Colman, P. G., & Cohney, S. J. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03855.x · Cited by 147
Management of post‐transplant diabetes: immunosuppression, early prevention, and novel antidiabetics
Hecking, M., Sharif, A., Eller, K., & Jenssen, T. G. (2020) · Transplant International · doi:10.1111/tri.13783 · Cited by 125
Self-citationNew-Onset Diabetes After Kidney Transplantation: Prevalence, Risk Factors, and Management
Sarno, G., Muscogiuri, G., & Rosa, P. D. (2012) · Transplantation · doi:10.1097/tp.0b013e31824db97d · Cited by 75
Immunosuppression and Post-transplant Hyperglycemia
Montero, N., & Pascual, J. (2015) · Current Diabetes Reviews · doi:10.2174/1573399811666150331160846 · Cited by 57
New-onset diabetes after transplantation: Risk factors and clinical impact
Räkel, A., & Karelis, A. D. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.09.003 · Cited by 52
Langsford, D., & Dwyer, K. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i10.1132 · Cited by 44
Káposztás, Z., Gyürüs, É., & Kahan, B. D. (2011) · Transplantation Proceedings · doi:10.1016/j.transproceed.2011.04.008 · Cited by 41
New-onset diabetes after kidney transplant in children
Garro, R., Warshaw, B. L., & Felner, E. I. (2014) · Pediatric Nephrology · doi:10.1007/s00467-014-2830-7 · Cited by 39
Prasad, N., Gurjer, D., BHADAURIA, D. S., Gupta, A. K., Srivastava, A., Kaul, A., Jaiswal, A. K., Yadav, B., Yadav, S., & Sharma, R. K. (2014) · Nephrology · doi:10.1111/nep.12209 · Cited by 35
Prevention and management of new-onset diabetes mellitus in kidney transplantation.
Khong, M. J., & Chong, C. P. (2014) · PubMed · Cited by 32
Hornum, M., Lindahl, J. P., von Zur‐Mühlen, B., Jenssen, T. G., & Feldt‐Rasmussen, B. (2013) · Transplant International · doi:10.1111/tri.12112 · Cited by 29
Self-citationNew-Onset Diabetes and Nephropathy after Renal Transplantation
Guitard, J., Rostaing, L. P. E., & Kamar, N. (2011) · Contributions to nephrology · doi:10.1159/000325778 · Cited by 27
Santos, A. H., Chen, C., Casey, M. J., Womer, K. L., & Wen, X. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx281 · Cited by 25
Shin, S. H., Han, D. J., Kim, Y. H., Han, S., Choi, B. H., Jung, J. H., & Cho, H. K. (2014) · Transplantation · doi:10.1097/tp.0000000000000214 · Cited by 24
Prevention and management of transplant-associated diabetes
Jenssen, T. G., & Hartmann, A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.628936 · Cited by 18
Self-citationKim, J.-M., Jung, H., Kwon, H. E., Ko, Y., Jung, J. H., Kwon, H., Kim, Y. H., Jun, T. J., Hwang, S., & Shin, S. H. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000002028 · Cited by 17
pre-existing diabetes and PTDM in kidney transplant recipients: how to handle immunosuppression
Chevallier, E., Jouvé, T., Rostaing, L. P. E., Malvezzi, P., & Noble, J. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1851596 · Cited by 16
Housawi, A. A., Abdulrahman, M., Idris, M. A., Elhakimi, W., Akhtar, M., Hammam, M., Aldajani, A. A., Aljamaan, Y. M., & Alshahri, H. (2018) · Saudi Journal of Kidney Diseases and Transplantation · doi:10.4103/1319-2442.239641 · Cited by 12
Ekberg, J., Ekberg, H., Jespersen, B., Källén, R., Skov, K., Olausson, M., Mjörnstedt, L., & Lindnér, P. (2014) · Transplantation Research · doi:10.1186/2047-1440-3-12 · Cited by 8
Abbas, M. H., Ismail, M. I., Deeb, S. A. E., Nagib, A. M., Hassan, N. M. A. E.-F., Refaie, A. F., Maghrabi, H. M. E., Denewar, A., & Bakr, M. A. (2015) · PubMed · Cited by 8
Gosmanova, E. O., Tangpricha, V., & Gosmanov, A. R. (2012) · Endocrine Practice · doi:10.4158/ep12016.ra · Cited by 6
Jin, L. G., Lim, S. W., Jin, J., Chung, B. H., & Yang, C. W. (2016) · Translational research · doi:10.1016/j.trsl.2016.03.012 · Cited by 6
Xue, M., Lv, C., Chen, X., Huang, X., Sun, Q., Wang, T., Liang, J., Zhang, Y., He, S., Gao, J., et al. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12356 · Cited by 5
Posttransplantionsdiabetes: Diagnostische und therapeutische Strategien
Eckhard, M., Dieterle, C. D., Brendel, M. D., Bretzel, R. G., & Landgraf, R. (2010) · Der Diabetologe · doi:10.1007/s11428-010-0567-x · Cited by 3
Post-transplantation diabetes mellitus: an overview
Sklyanik, I. A., Шамхалова, М. Ш., & Shestakova, M. V. (2015) · Diabetes Mellitus · doi:10.14341/dm2015220-31 · Cited by 3
Induction immunosuppression and post-transplant diabetes mellitus: a propensity-matched cohort study
Gupta, S., Mostofsky, E., Motiwala, S. R., Hage, A., & Mittleman, M. A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1248940 · Cited by 3
Santos, A. H., Leghrouz, M. A., Bueno, E. P., & Andreoni, K. A. (2021) · International Urology and Nephrology · doi:10.1007/s11255-021-02936-1 · Cited by 3
Drugs that act on the immune system: cytokines and monoclonal antibodies
Spoerl, D., & Bircher, A. J. (2012) · Side effects of drugs annual · doi:10.1016/b978-0-444-59499-0.00037-4 · Cited by 2
New-onset diabetes after transplantation: focus on treatment strategies
Marino, A., Inankur, A., & Tannock, L. R. (2011) · Diabetes Management · doi:10.2217/dmt.11.33 · Cited by 1
Diabetes in Kidney Transplant Recipients
Dhital, S. M. (2018) · Springer eBooks · doi:10.1007/978-3-030-00132-2_10 · Cited by 1
Korson, D. (2016) · ScholarWorks - GVSU (Grand Valley State University) · Cited by 1
Посттрансплантационный сахарный диабет. Обзор литературы
Шамхалова, М. Ш., Shestakova, M. V., & Sechenov, I. M. (2015)
Management of new onset dysglycemia in transplant recipients
Sharif, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00045-1
Current awareness: Pharmacoepidemiology and drug safety
(2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1857
Post-transplantasjons-diabetes mellitus i nyretransplanterte pasienter: En bihormonell sykdom
Egeland, E. J. (2015) · NVA (Nasjonalt vitenarkiv)
Halden, T. A. S. (2012) · NVA (Nasjonalt vitenarkiv)
Long-Term Risk of New-onset Diabetes in Pediatric Solid Organ Transplant Recipients
Chanchlani, R. (2016) · TSpace (University of Toronto)
Post-transplant Diabetes Mellitus: Immunosuppressive Agent Adjustment and Outcome
Sutantio, J. D., P, B. T. A. A., & Hidayati, E. L. (2019) · Journal of Case Reports · doi:10.17659/01.2019.0066
Metadata
- Authors
- Aasebo, W., Midtvedt, K., Valderhaug, T. G., Leivestad, T., Hartmann, A., Reisaeter, A. V., Jenssen, T., & Holdaas, H.
- Affiliations
- Oslo University Hospital (NO)
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-11-23
- Volume
- 25
- Issue
- 4
- Pages
- 1289-1293
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2115385656
- Cited by
- 38
- References
- 22
- Citations by year
- 2024: 2 · 2023: 1 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 2 · 2015: 6 · 2014: 6 · 2013: 1 · 2012: 3
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nephrology Dialysis Transplantation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- basiliximab, kidney transplantation, post-transplant diabetes mellitus, impaired glucose tolerance, impaired fasting glucose, glucose homeostasis, induction therapy, regulatory T cells, immunosuppression, oral glucose tolerance test
- MeSH terms
- Basiliximab, Antibodies, Monoclonal, Blood Glucose, Female, Glucose, Glucose Tolerance Test, Graft Survival, Homeostasis, Humans, Immunosuppressive Agents, Male, Middle Aged, Recombinant Fusion Proteins, Retrospective Studies, Kidney Transplantation, Treatment Outcome, Glucose Intolerance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.